Pre-op MMC effective for recurrent pterygium

Article

Subconjunctival mitomycin C (MMC) injections followed by bare sclera pterygium excision is successful and cost-effective for the treatment of recurrent pterygium associated with symblepharon, according to a recently published study.

Subconjunctival mitomycin C (MMC) injections followed by bare sclera pterygium excision is successful and cost-effective for the treatment of recurrent pterygium associated with symblepharon, according to a recently published case study

Dr Isyaku Mohammed et al., Department of Ophthalmology, Aminu Kano Teaching Hospital, Kano, Nigeria, conducted a case report on a 31-year-old male with recurrent pterygium.

Low-dose (0.02%) MMC was administered to the patient one month before bare sclera excision of multicurrent pterygium. At the same time, symblepharolysis was performed including further application of MMC intraoperatively to the upper conjunctival fornix.

Overall, MMC injections followed by excision are cost-effective and easily performed. It is also safe and effective. There was no recurrence or complications recorded during the one-year follow-up, apart from a Tenon granuloma that was excised. The injections are safe and effective when combined with intraoperative application to the conjunctival fornix.

The abstract can be found in the latest edition of the journal Clinical Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.